---
title: "Povetacicept (ALPN-303): A Dual BAFF/APRIL Fusion Protein Nears Approval for IgA Nephropathy (September 9, 2026) | PepTracker Pro Blog"
url: https://peptrackerpro.com/blog/povetacicept-alpn-303-vertex-alpine-immune-sciences-taci-vtd-fc-dual-baff-april-inhibitor-fusion-protein-iga-nephropathy-igan-rainier-phase-3-ruby-3-upcr-proteinuria-gd-iga1-bla-accelerated-approval-pdufa-breakthrough-therapy-september-9-2026
description: "Povetacicept (ALPN-303) is an investigational once-monthly fusion protein that blocks both BAFF and APRIL, the cytokines that keep antibody-producing B cells alive. Built from an engineered TACI decoy fused to an antibody Fc, it targets the B-cell driver of IgA nephropathy. A positive Phase 3 RAINIER interim analysis and an FDA accelerated-approval filing (PDUFA November 30, 2026) have made it one of the most closely watched biologics in nephrology."
lang: en
---

Skip to main content

**Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer)

Research & Compounds

Research & Compounds

# Povetacicept (ALPN-303): A Dual BAFF/APRIL Fusion Protein Nears Approval for IgA Nephropathy (September 9, 2026)

PepTracker Pro Research Team September 9, 2026 10 min read

## Table of Contents

- One molecule against two B-cell signals
- What povetacicept is made of
- Why BAFF and APRIL matter in IgA nephropathy
- The Phase 3 RAINIER result
- The broader program: RUBY-3 and beyond
- How it is given
- Regulatory status and the road to approval
- Safety and open questions
- Where povetacicept fits among new IgAN therapies
- Why povetacicept matters

## One molecule against two B-cell signals

Povetacicept, known by its development code ALPN-303, is an investigational biologic designed to switch off two of the immune system's most important B-cell survival signals at the same time. Those signals are two closely related cytokines: BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Both keep antibody-producing B cells and plasma cells alive and active, and when they are overactive they help drive a range of autoimmune and antibody-mediated diseases. Most drugs target one cytokine or one cell type; povetacicept is unusual because a single, once-monthly injection soaks up both BAFF and APRIL before they can reach the cells that depend on them.

## What povetacicept is made of

Povetacicept is a recombinant fusion protein. The immune cells that respond to BAFF and APRIL carry three receptors - BAFF-R, TACI and BCMA - and TACI is the one natural receptor that binds both cytokines. Alpine Immune Sciences used its protein-engineering ('variant Ig domain') platform to take the business end of TACI, its extracellular domain, mutate it for much stronger binding, and fuse it to the Fc region of an antibody. The result, described in the literature as a 'TACI vTD-Fc' (variant TACI domain-Fc), acts as a high-affinity decoy: it grabs circulating BAFF and APRIL and holds onto them, so they can no longer signal through any of the three receptors. The antibody Fc portion gives the molecule a long half-life, which is what allows dosing roughly once a month rather than weekly.

## Why BAFF and APRIL matter in IgA nephropathy

Povetacicept's lead target is IgA nephropathy (IgAN), one of the most common causes of primary glomerular disease worldwide and a frequent path to kidney failure in otherwise young, healthy adults. Over the past decade researchers have reframed IgAN as fundamentally a B-cell problem. APRIL in particular drives mucosal B cells to overproduce an abnormal, poorly galactosylated form of immunoglobulin A1 called galactose-deficient IgA1 (Gd-IgA1). The body then makes autoantibodies against Gd-IgA1, and the resulting immune complexes deposit in the kidney's filtering units (the glomeruli), triggering inflammation, leakage of protein into the urine (proteinuria) and, over years, progressive loss of kidney function. Because APRIL sits so far upstream in this cascade, blocking it - and BAFF alongside it - is expected to turn down production of Gd-IgA1 and its autoantibodies at the source.

## The Phase 3 RAINIER result

The pivotal trial is RAINIER, a randomized, double-blind, placebo-controlled Phase 3 study that enrolled roughly 600 adults with biopsy-confirmed IgA nephropathy (about 557 in the main cohort plus a smaller exploratory cohort of around 48). Patients received once-monthly subcutaneous povetacicept or placebo on top of standard supportive care. In March 2026 Vertex reported a positive prespecified interim analysis at Week 36: povetacicept reduced the urine protein-to-creatinine ratio (UPCR) by about 52% from baseline and by a statistically significant, clinically meaningful roughly 50% (49.8%) compared with placebo, hitting the primary endpoint and all key secondary endpoints. Adverse events were mostly mild to moderate. Proteinuria reduction of this magnitude is exactly the kind of effect that can support accelerated approval in IgAN, because heavy proteinuria is one of the strongest predictors of kidney decline.

## The broader program: RUBY-3 and beyond

RAINIER did not come out of nowhere. It was built on RUBY-3, a Phase 1/2 'basket' study that tested povetacicept across several forms of autoimmune glomerulonephritis at once - IgA nephropathy, primary membranous nephropathy, lupus nephritis, and ANCA-associated vasculitis with kidney involvement. Updated RUBY-3 data presented at the American Society of Nephrology's Kidney Week showed early efficacy signals (reductions in proteinuria and disease-relevant antibodies) with a generally favorable safety profile, which is what justified moving into a large Phase 3 trial. Because povetacicept targets a shared upstream driver of antibody responses rather than a single disease-specific molecule, Vertex is also developing it in generalized myasthenia gravis and studying it in other B-cell-mediated conditions - a one-mechanism, many-diseases strategy.

## How it is given

Povetacicept is administered as a subcutaneous injection about once every four weeks. That schedule is supported by the molecule's pharmacology: in dose-ranging studies it covered free APRIL for two to three weeks at lower doses and four weeks or more at higher doses, so a monthly dose keeps both cytokines suppressed between injections. A convenient monthly, self-injectable schedule is a practical advantage for a chronic outpatient autoimmune disease, where adherence over years matters as much as the size of the initial effect.

## Regulatory status and the road to approval

The FDA has granted povetacicept Breakthrough Therapy Designation for IgA nephropathy, a status reserved for therapies that may offer substantial improvement over available options. On June 1, 2026 the agency accepted a Biologics License Application (BLA) for accelerated approval of povetacicept in IgAN and set a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. Accelerated approval would be based on the proteinuria (UPCR) surrogate endpoint, with the requirement that longer-term kidney-function data (change in eGFR) confirm the benefit; those confirmatory data continue to accrue in the ongoing trial. Nothing here is approved yet - povetacicept remains investigational until the FDA acts.

## Safety and open questions

Because povetacicept dampens antibody-producing immunity, its safety considerations follow the BAFF/APRIL-inhibitor class: potential reductions in immunoglobulin levels, blunted responses to vaccines, and a possible increase in infections, all of which require monitoring; live vaccines are generally avoided during B-cell-directed therapy. In trials to date it has been generally well tolerated, with adverse events mostly mild or moderate, but long-term and repeat-dose safety, along with effects in pregnancy and breastfeeding, are not yet established. The efficacy data so far rest on a proteinuria surrogate; whether that reliably translates into preserved kidney function and fewer patients reaching kidney failure is the central question the full RAINIER readout must answer.

## Where povetacicept fits among new IgAN therapies

IgA nephropathy has gone from a therapeutic desert to one of nephrology's most crowded pipelines. Several classes are converging: targeted-release corticosteroids, endothelin and dual endothelin/angiotensin receptor blockers, complement inhibitors, and B-cell-directed agents aimed at APRIL and BAFF. Within the B-cell group, some drugs block APRIL alone (for example sibeprenlimab and zigakibart), while povetacicept and telitacicept block both APRIL and BAFF via a TACI-based decoy. The open scientific debate is whether hitting both cytokines is meaningfully better than APRIL alone, or whether it simply broadens immune suppression; head-to-head data do not yet exist, so cross-trial comparisons should be read cautiously.

## Why povetacicept matters

Povetacicept is a marker of two shifts at once. Clinically, it is part of the transformation of IgA nephropathy into a disease with mechanism-specific, disease-modifying therapy rather than only blood-pressure control and supportive care. Strategically, it shows how engineered fusion proteins - decoy receptors tuned for higher affinity than anything in nature - are being used to neutralize cytokines with a precision and dosing convenience that first-generation biologics could not match, and it explains why Vertex Pharmaceuticals entered autoimmune nephrology by acquiring Alpine Immune Sciences in 2024. With a positive Phase 3 interim analysis and a November 30, 2026 FDA decision date, povetacicept is one of the most closely watched biologics in kidney medicine. As always, this is background information, not medical advice; IgA nephropathy and related glomerular diseases require specialist diagnosis and management with a qualified clinician.

Ready to track your peptide research?

Open PepTracker Pro (https://app.peptrackerpro.com/)

PepTracker Pro Research Team

The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.

## Citations

1. [1] Vertex Announces Positive Week 36 Interim Analysis Results in the RAINIER Phase 3 Trial of Povetacicept in IgA Nephropathy - Vertex Pharmaceuticals (March 9, 2026) Source (https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results)
2. [2] Vertex Announces US FDA Acceptance of BLA for Accelerated Approval of Povetacicept in IgA Nephropathy - Vertex Pharmaceuticals (June 1, 2026) Source (https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-acceptance-biologics-license-application)
3. [3] RAINIER: Povetacicept Achieves Primary and All Secondary Endpoints for IgAN - HCPLive Source (https://www.hcplive.com/view/ranier-povetacicept-achieves-primary-and-all-secondary-endpoints-for-igan)
4. [4] Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study at ASN Kidney Week - Vertex Pharmaceuticals Source (https://news.vrtx.com/news-releases/news-release-details/vertex-presents-updated-phase-12-data-ruby-3-study-continue)
5. [5] Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL - Frontiers in Immunology (2025) Source (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1533093/full)
6. [6] FDA Sets Target Date for Povetacicept in IgA Nephropathy (PDUFA Nov 30, 2026) - Rheumatology Advisor Source (https://www.rheumatologyadvisor.com/news/fda-accepts-povetacicept-application-iga-nephropathy/)

**Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer → (https://peptrackerpro.com/research-disclaimer)

## Related Articles

Research & Compounds cover image (https://peptrackerpro.com/blog/sotatercept-winrevair-actriia-fc-activin-signaling-inhibitor-pah-stellar-zenith-hyperion-july-18-2026)

Research & Compounds ### Sotatercept (Winrevair): The Activin Trap That Made Pulmonary Arterial Hypertension a Treatable Disease, Not Just a Managed One (July 18, 2026) (https://peptrackerpro.com/blog/sotatercept-winrevair-actriia-fc-activin-signaling-inhibitor-pah-stellar-zenith-hyperion-july-18-2026)

Merck's sotatercept (Winrevair) is a fusion protein that traps activin A, activin B, myostatin and GDF-11 - and it changed what pulmonary arterial hypertension therapy can aim for. STELLAR delivered a 40.8-meter gain in 6-minute walk distance; ZENITH cut death, transplant and hospitalization by 76% in the sickest patients and led to an expanded FDA label on October 27, 2025. Here is how the broadest activin-axis drug compares with the selective antibodies chasing the same biology.

PepTracker Pro Team

July 18, 2026 9 min read

Read (https://peptrackerpro.com/blog/sotatercept-winrevair-actriia-fc-activin-signaling-inhibitor-pah-stellar-zenith-hyperion-july-18-2026)

Research & Compounds cover image (https://peptrackerpro.com/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026)

Research & Compounds ### Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026) (https://peptrackerpro.com/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026)

Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype.

PepTracker Pro Team

July 23, 2026 8 min read

Read (https://peptrackerpro.com/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026)

Research & Compounds cover image (https://peptrackerpro.com/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026)

Research & Compounds ### Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026) (https://peptrackerpro.com/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026)

Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.

PepTracker Pro Team

July 25, 2026 8 min read

Read (https://peptrackerpro.com/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026)

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "name": "PepTracker Pro",
    "url": "https://peptrackerpro.com",
    "logo": "https://peptrackerpro.com/favicon.png",
    "description": "Evidence-based educational resource dedicated to improving peptide research literacy.",
    "contactPoint": {
      "@type": "ContactPoint",
      "email": "hello@peptrackerpro.com",
      "contactType": "customer support"
    },
    "sameAs": []
  },
  {
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Povetacicept (ALPN-303): A Dual BAFF/APRIL Fusion Protein Nears Approval for IgA Nephropathy (September 9, 2026)",
    "description": "Povetacicept (ALPN-303) is an investigational once-monthly fusion protein that blocks both BAFF and APRIL, the cytokines that keep antibody-producing B cells alive. Built from an engineered TACI decoy fused to an antibody Fc, it targets the B-cell driver of IgA nephropathy. A positive Phase 3 RAINIER interim analysis and an FDA accelerated-approval filing (PDUFA November 30, 2026) have made it one of the most closely watched biologics in nephrology.",
    "datePublished": "2026-09-09",
    "dateModified": "2026-09-09",
    "author": {
      "@type": "Organization",
      "name": "PepTracker Pro Research Team",
      "url": "https://peptrackerpro.com"
    },
    "publisher": {
      "@type": "Organization",
      "name": "PepTracker Pro",
      "logo": {
        "@type": "ImageObject",
        "url": "https://peptrackerpro.com/favicon.png"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://peptrackerpro.com/blog/povetacicept-alpn-303-vertex-alpine-immune-sciences-taci-vtd-fc-dual-baff-april-inhibitor-fusion-protein-iga-nephropathy-igan-rainier-phase-3-ruby-3-upcr-proteinuria-gd-iga1-bla-accelerated-approval-pdufa-breakthrough-therapy-september-9-2026"
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://peptrackerpro.com"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Blog",
        "item": "https://peptrackerpro.com/blog"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "Povetacicept (ALPN-303): A Dual BAFF/APRIL Fusion Protein Nears Approval for IgA Nephropathy (September 9, 2026)",
        "item": "https://peptrackerpro.com/blog/povetacicept-alpn-303-vertex-alpine-immune-sciences-taci-vtd-fc-dual-baff-april-inhibitor-fusion-protein-iga-nephropathy-igan-rainier-phase-3-ruby-3-upcr-proteinuria-gd-iga1-bla-accelerated-approval-pdufa-breakthrough-therapy-september-9-2026"
      }
    ]
  }
]
```